[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY34847A - Preparacion sólida - Google Patents

Preparacion sólida

Info

Publication number
UY34847A
UY34847A UY0001034847A UY34847A UY34847A UY 34847 A UY34847 A UY 34847A UY 0001034847 A UY0001034847 A UY 0001034847A UY 34847 A UY34847 A UY 34847A UY 34847 A UY34847 A UY 34847A
Authority
UY
Uruguay
Prior art keywords
solid preparation
present
saccharide
methyl
salt
Prior art date
Application number
UY0001034847A
Other languages
English (en)
Inventor
Misaki Masafumi
Takahara Maiko
Yamane Ikurou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34847A publication Critical patent/UY34847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una preparación sólida con excelentes propiedades de desintegración y estabilidad de preservación. La presente inv ención se refiere a una preparación sólida que contiene (1) 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2H)-pirimidinil]metil]-4-fluorobenzonitrilo (compuesto(A)) o una sal del mismo, (2) un sacárido, y (3) fumarato de estearil sodio. Además, la presente invención se refiere a una preparación sólida que contiene (1) compuesto (A) o una sal del mismo, (2) un sacárido, y (3) ácido esteárico o talco en una parte de un comprimido desnudo.
UY0001034847A 2012-06-05 2013-06-04 Preparacion sólida UY34847A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012128360 2012-06-05

Publications (1)

Publication Number Publication Date
UY34847A true UY34847A (es) 2014-01-31

Family

ID=48670046

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034847A UY34847A (es) 2012-06-05 2013-06-04 Preparacion sólida

Country Status (10)

Country Link
US (2) US9486411B2 (es)
EP (1) EP2854772A1 (es)
JP (1) JP6122879B2 (es)
KR (1) KR102145641B1 (es)
CN (1) CN104519874B (es)
AR (1) AR092843A1 (es)
CA (1) CA2874820C (es)
TW (1) TWI580444B (es)
UY (1) UY34847A (es)
WO (1) WO2013183784A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020090971A1 (ja) * 2018-10-31 2021-09-16 富士フイルム株式会社 抗腫瘍剤を含む錠剤
WO2020090970A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む医薬組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005067976A2 (en) 2004-01-20 2005-07-28 Novartis Ag Direct compression formulation and process
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
PE20070522A1 (es) 2005-09-14 2007-07-11 Takeda Pharmaceutical 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
RS53230B (en) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited CONDENSED CYCLICAL UNITS AS GPR40 RECEPTOR MODULATORS
KR20170127074A (ko) 2006-09-13 2017-11-20 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
JP5260507B2 (ja) 2006-10-19 2013-08-14 武田薬品工業株式会社 インドール化合物
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
CA2677736A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
CL2008000727A1 (es) * 2007-03-13 2008-10-17 Takeda Pharmaceutical Granulo compuesto por 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluorobenzonitrilo o una de sus sales y un aditivo que no comprende celulosa microcristalina; preparacion solida; comprimido y procedimi
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
WO2009144974A1 (ja) * 2008-05-29 2009-12-03 第一三共株式会社 製剤における滑沢剤成分の混合状態をモニターする方法
WO2011013639A1 (ja) 2009-07-28 2011-02-03 武田薬品工業株式会社 錠剤
JP5421945B2 (ja) * 2010-03-10 2014-02-19 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
WO2012062691A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treating hcv infections

Also Published As

Publication number Publication date
KR20150021544A (ko) 2015-03-02
US9757377B2 (en) 2017-09-12
AR092843A1 (es) 2015-05-06
TWI580444B (zh) 2017-05-01
TW201400147A (zh) 2014-01-01
KR102145641B1 (ko) 2020-08-18
CN104519874B (zh) 2018-08-03
CN104519874A (zh) 2015-04-15
US20170007607A1 (en) 2017-01-12
WO2013183784A1 (en) 2013-12-12
EP2854772A1 (en) 2015-04-08
US9486411B2 (en) 2016-11-08
CA2874820C (en) 2020-06-09
CA2874820A1 (en) 2013-12-12
US20150141447A1 (en) 2015-05-21
JP2015518815A (ja) 2015-07-06
JP6122879B2 (ja) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2015017374A (es) Articulos para el cuidado personal.
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
AR065698A1 (es) Preparacion solida
IN2015DN01156A (es)
CA2871471C (en) Dna-pk inhibitors
EA201270204A1 (ru) Таблетка
BR112015020466A2 (pt) inibidores de cdc7
EA201690357A1 (ru) Лекарственные формы с замедленным высвобождением для ингибитора jak1
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
GEP20166554B (en) Nitrogenated heterocyclic compound
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
MY155938A (en) Oral pharmaceutical composition
MY173573A (en) Pyridin-4-yl derivatives
BR112013022213A2 (pt) administração parenteral de tapentadol
BR112014026828A2 (pt) compostos de triazolo como inibidores de pde10
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
MX355885B (es) Composición farmacéutica de administración oral.
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
UY34847A (es) Preparacion sólida
EA201990093A1 (ru) Двухкомпонентная композиция
BR112015023013A2 (pt) inibidores de quinase cdk9

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528